Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.


Related Content

PDUFA V Action Heats Up On Hill With House Hearings In February
Drug Shortage Bills Likely Drivers Of PDUFA Add-ons
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
FDA Biomedical Innovation Initiative Draws On Familiar Themes
Firms Navigate Social Media Safely Following Loss Of Facebook Protection
Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V
Avastin’s Breast Cancer Claim: Will FDA’s Hamburg Take A Middle Road?
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts